A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer.

Trial Profile

A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Mar 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Nov 2007 Trial centre added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top